Insitro

October 01, 2020

Merck’s Roger Perlmutter joins board of AI drug discovery startup insitro

September 30, 2020

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

September 30, 2020

insitro's Mary Rozenman Named to Business Insider's 30 Under 40 in Healthcare

May 26, 2020

Exclusive: Machine Learning Company insitro Raises $143 Million To Bridge Biology And AI

May 26, 2020

insitro Adds $143M to Fuel Machine Learning-Driven Drug Development

November 21, 2019

AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron

November 11, 2019

Daphne Koller, A Star Professor—And Her Radical, AI-Powered Plan To Discover New Drugs

November 11, 2019

Our Founder & CEO on the List of 2019's Fiercest Women in Life Sciences

September 17, 2019

insitro on the list of AI 50: America’s Most Promising Artificial Intelligence Companies

September 17, 2019

Coursera Cofounder Daphne Koller Melds AI And Biology In Drug Startup Insitro

September 16, 2019

Our founder and CEO Daphne Koller has been selected as one of Inc.’s 100 Female Founders

July 09, 2019

An audience with Daphne Koller

May 02, 2019

The start-up striving to accelerate drug discovery

April 16, 2019

Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs

April 16, 2019

Stealthy Insitro opens up—starting with Gilead deal worth up to $1.05B

April 16, 2019

In a test for AI, a buzzy machine learning startup inks drug discovery deal with Gilead

April 16, 2019

Gilead teams with startup to turn machine learning on fatty liver disease

April 16, 2019

Gilead Sciences, insitro Launch Up-to-$1B+ AI-Based NASH Drug Collaboration

April 16, 2019

A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease

April 16, 2019

With $150M and a new NASH discovery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

April 16, 2019

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis

March 19, 2019

A data-driven exploration of human biology, a talk presented at the MARS conference

February 18, 2019

On GPS: Koller talks AI & healthcare

October 17, 2018

Daphne Koller, Founder & CEO of Insitro - In Conversation with Carlos Bustamante

October 15, 2018

Samsung CEO Summit: Human Biology through the Lens of Data

May 02, 2018

Out to ‘rethink the drug design process,’ AI star Daphne Koller is creating a new machine learning venture at insitro with some heavyweight backers

May 02, 2018

Daphne Koller, A-list backers unite to create machine learning drug R&D startup

May 02, 2018

AI researcher Daphne Koller heading new machine learning drug discovery venture

May 01, 2018

Recent news and coverage of insitro

Merck’s Roger Perlmutter joins board of AI drug discovery startup insitro

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

insitro's Mary Rozenman Named to Business Insider's 30 Under 40 in Healthcare

Exclusive: Machine Learning Company insitro Raises $143 Million To Bridge Biology And AI

insitro Adds $143M to Fuel Machine Learning-Driven Drug Development

AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron

Daphne Koller, A Star Professor—And Her Radical, AI-Powered Plan To Discover New Drugs

Our Founder & CEO on the List of 2019's Fiercest Women in Life Sciences

insitro on the list of AI 50: America’s Most Promising Artificial Intelligence Companies

Coursera Cofounder Daphne Koller Melds AI And Biology In Drug Startup Insitro

Our founder and CEO Daphne Koller has been selected as one of Inc.’s 100 Female Founders

An audience with Daphne Koller

The start-up striving to accelerate drug discovery

Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs

Stealthy Insitro opens up—starting with Gilead deal worth up to $1.05B

In a test for AI, a buzzy machine learning startup inks drug discovery deal with Gilead

Gilead teams with startup to turn machine learning on fatty liver disease

Gilead Sciences, insitro Launch Up-to-$1B+ AI-Based NASH Drug Collaboration

A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease

With $150M and a new NASH discovery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis

A data-driven exploration of human biology, a talk presented at the MARS conference

On GPS: Koller talks AI & healthcare

Daphne Koller, Founder & CEO of Insitro - In Conversation with Carlos Bustamante

Samsung CEO Summit: Human Biology through the Lens of Data

Out to ‘rethink the drug design process,’ AI star Daphne Koller is creating a new machine learning venture at insitro with some heavyweight backers

Daphne Koller, A-list backers unite to create machine learning drug R&D startup

AI researcher Daphne Koller heading new machine learning drug discovery venture

Backed by big-name VCs, this startup is turning machine learning on drug discovery